Objectives: To study the diagnostic efficacy of low-dose iohexol (90 mg iodine/kg body weight) for intravenous urography.
Materials And Methods: Intravenous urography was performed using low-dose iohexol in 50 patients with various urinary complaints. Patients with elevated blood urea and serum creatinine levels were excluded. The urographic films were evaluated with regard to diagnostic information about renal parenchyma, calyces, collecting system and overall image. Patients were also observed for adverse reactions.
Results: A satisfactory diagnosis could be reached in 94% of patients with low-dose iohexol. Only a minor reaction in the form of heat sensation was noted in 1 patient, which did not require any treatment.
Conclusion: Iohexol is safe and very useful diagnostically in a low dose for routine intravenous urography.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000071849 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BPE on contrast-enhanced mammography: relationship with breast density, age and menopausal status.
Radiol Med
November 2024
Department of Radiological, Oncological and Pathological Sciences, Sapienza-University of Rome, 00161, Rome, Italy.
Purpose: This retrospective study aimed to evaluate the relationship between BPE on CEM and breast density, age and menopausal status.
Material And Methods: Our analysis included all women eligible for CEM as a second-level examination in the diagnostic phase in a 12-month period. CEM were performed on a dedicated low-dose digital mammography unit after the injection of 1.
Comparative long-term efficacy and safety of two paclitaxel-coated balloons with different coating strategies for the treatment of drug-eluting coronary stent restenosis.
Catheter Cardiovasc Interv
November 2024
ISAResearch Zentrum, Kardiologie, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
Background: We previously showed non-inferiority of a low-dose paclitaxel-coated balloon (PCB) with citrate excipient (Agent PCB) as compared to normal-dose iopromide excipient (SeQuent Please PCB) in terms of angiographic and clinical endpoints at 12 months. The long-term clinical efficacy and safety of Agent PCB is not defined.
Methods: 262 patients (323 DES-ISR lesions) were enrolled in this study and treated with either Agent PCB (125 patients, 151 lesions) in the ISAR-DESIRE 3a trial or with SeQuent Please PCB (137 patients, 172 lesions) in the setting of the randomized ISAR-DESIRE 3 trial with similar in- and exclusion criteria serving as historical control arm.
Double low-dose computed tomography (CT) angiography of craniocervical arteries using a test bolus of diluted contrast medium and a personalized contrast protocol.
Clin Radiol
November 2024
Department of Radiology, Wujin Hospital Affiliated to Jiangsu University, Wujin Clinical College of Xuzhou Medical University, Changzhou 213002, Jiangsu, China. Electronic address:
Aim: To prospectively assess the value of a test bolus of diluted contrast medium (CM) combined with a personalized contrast protocol in craniocervical computed tomography angiography (cc-CTA) with low radiation and CM doses.
Materials And Methods: Eighty-six consecutive subjects were divided into two groups at random (43 in each one): group A: 100/Sn140 kVp, filtered back-projection reconstruction, iopromide (370 mgI/ml) 50 ml; group B: 80/Sn140 kVp, iterative reconstruction, iodixanol (270 mgI/ml). In group B, the test bolus contained 27 ml of diluted CM, a personalized protocol with low-concentration CM was used for angiography, and the test bolus injection duration in angiography remained the same.
Novel radiopaque ethanol injection: physicochemical properties, animal experiments, and clinical application in vascular malformations.
Mil Med Res
June 2024
Vascular Anomaly Center, Department of Interventional Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Article Synopsis
- A new study investigates a radiopaque ethanol injection (REI) that combines iopromide and ethanol to improve visibility during interventional therapies for vascular malformations, addressing the risks associated with using pure ethanol.
- The research involved in vivo testing on 82 male New Zealand white rabbits, comparing different doses of REI and ethanol in procedures like peripheral vein sclerosis and kidney embolization, alongside evaluating safety and pharmacokinetics.
- Finally, a cohort study was conducted with 6 patients suffering from peripheral venous malformations to assess the clinical safety and effectiveness of the new REI treatment from June to August 2023.
Canine preclinical safety evaluation of a multimodal nanoparticle agent (Nanotrast-CF800) for image-guided cancer surgery.
PLoS One
June 2024
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Surgical oncology often requires the use of contrast-enhanced cross-sectional imaging preoperatively to characterize solitary tumours and identify sentinel lymph nodes. Intraoperative optical guidance can effectively aid tissue-sparing tumour excision and locate sentinel lymph nodes. Nanotrast-CF800 (CF800) is a novel dual-modality contrast agent, which co-encapsulates iohexol and indocyanine green (ICG) within a liposomal nanoparticle.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!